Name: Małopolskie Centrum Kliniczne
Address: ..., Kraków, Małopolskie, 30-149
Telephone: 881 355 639

FORMULARZ ZGŁOSZENIOWY

First name and last name *

Imię

Nazwisko

Email *

Select a study from the list

Message content *

Wyrażam zgodę na przetwarzanie przez firmę Małopolskie Centrum Kliniczne moich danych osobowych zawartych w powyższym formularzu rejestracyjnym w celu mojego ewentualnego uczestnictwa w bieżących i przyszłych rekrutacjach do badań klinicznych realizowanych przez firmę Małopolskie Centrum Kliniczne która obejmuje także kontakt drogą elektroniczną (email, sms) i kontakt telefoniczny ze mną jako ochotnikiem do badań klinicznych. zgodnie z ustawą z dnia 18.07.2002 r. o świadczeniu usług drogą elektroniczną (Dz.U. Nr 144, poz.1204 z późn. zm.) i Art. 6 ust. 1 lit. f RODO.
Wyrażam zgodę na przetwarzanie danych osobowych, medycznych i danych o stylu życia do celów pełnej realizacji procesu rekrutacji do badań klinicznych, zgodnie Art. 6 ust. 1 lit. A, c, f RODO oraz art. 9 ust. 2 lit. a RODO w zw. z art. 37 f, a ustawy Prawo farmaceutyczne.
Wyrażam zgodę na przesyłanie mailem lub smsem ofert marketingowych zgodnie z Ustawą z dnia 18 lipca 2002 r. o świadczeniu usług drogą elektroniczną (Dz.U. 2017, poz. 1219).

LIST OF RESEARCH

Gout
Study description:
Phase III study to evaluate the efficacy and safety of tigulixostat in gout patients with hyperuricemia.
The main criteria that the patient must meet:
- • age from 18 to 85 years,
- • patients with hyperuricemia and history or presence of gout,
- • patients taking urate-lowering therapies,
As part of the study, patients are under constant care of the attending physician, receive free treatment and have free full diagnostics included in the clinical trial. The patient receives reimbursement for travel costs for each visit.

SUBMIT FOR THE TEST
Rheumatoid arthritis
Study description:
Phase III study for patients with active moderate-to-severe rheumatoid arthritis.
Main criteria:
- • Men and women aged ≥18 to ≤ 80 years,
- • Patients with active rheumatoid arthritis lasting at least 6 months.
As part of the study, patients are under the constant care of an attending physician, receive free treatment, and have free full diagnostics performed. The patient is reimbursed for travel expenses to each visit.

SUBMIT FOR THE TEST
Dermatomyositis or polymyositis
Study description:
Phase III study to evaluate the effectiveness of the study drug in participants with active dermatomyositis or polymyositis.
Main criteria:
- • age: at least 18 years old,
- • ddiagnosis of dermatomyositis or polymyositis.
- • ineffectiveness of current treatment.
As part of the study, patients are under constant care of the attending physician, receive free treatment and have free full diagnostics included in the clinical trial. The patient receives reimbursement for travel costs for each visit.

SUBMIT FOR THE TEST
Cardiological study for patients with high cardiovascular risk
Study description:
Phase III trial evaluating the effectiveness of PCSK9 in reducing major adverse cardiovascular events in participants at high cardiovascular risk.
Main criteria:
- • occurrence of serious atherosclerotic cardiovascular diseases,
- • patient treated with a moderate or high intensity statin (±LLT without statin),
- • patients taking a stable dose of all basic LLTs (including statins and non-statin-resistant drugs).
As part of the study, patients are under constant care of the attending physician, receive free treatment and have free full diagnostics included in the clinical trial. The patient receives reimbursement for travel costs for each visit.

SUBMIT FOR THE TEST
Atopic Dermatitis
Study description:
Phase Ib study assessing, among others, safety and tolerability of two different doses of the drug tested in patients with atopic dermatitis.
Main criteria:
- • age: 18 to 75 years,
- • diagnosed with moderate to severe atopic dermatitis at least 12 months before the first visit,
- • a history of inadequate response to treatment with topical medications, unless topical treatment is medically inadvisable (e.g. due to side effects, safety risks and/or previous intolerance).
As part of the study, patients are under constant care of the attending physician, receive free treatment and have free full diagnostics included in the clinical trial. The patient receives reimbursement for travel costs for each visit.

SUBMIT FOR THE TEST
Vitiligo
Study description:
Randomized, placebo-controlled, double-blind Phase III study evaluating the efficacy, safety and tolerability of Upadacitinib in adults and adolescents with vitiligo.
Main criteria:
- • Adults and adolescents ≥ 12 years of age,
- • Documented clinical diagnosis of NSV (non-segmental vitiligo),
- • The patient must not have a history of active skin disease other than vitiligo that could interfere with the assessment of vitiligo.
As part of the study, patients are under the constant care of a treating physician, receive free treatment and have free full diagnostics included in the clinical trial. The patient is reimbursed for travel expenses to each visit.

SUBMIT FOR THE TEST

APPLICATION FORM